GEORGIA BOARD OF PHARMACY
2 MLK Jr. Dr. SE, East Tower, 11th Floor, Atlanta, GA 30334
Minutes for August 19, 2026 Board Meeting

Board Members present:
Mr. Young Chang, President
Mr. Michael Farmer, Vice President
Dr. Michael Azzolin
Mr. Michael Brinson
Mr. James Bracewell
Dr. Cecil Cordle
Mr. Chuck Page

Board Staff present:
Mr. Clint Joiner, Executive Director
Dr. Michael Karnbach, Director, GDNA
Mr. Alec Mathis, Deputy Director, GDNA
Ms. Emilie Lobeck, Special Agent, GDNA
Ms. Itovia Evans, Deputy Director of Licensing
Mrs. Angela Johnson, Board Admin. Secretary
Mr. Tommy McNulty, Senior Assistant Attorney General

Visitors:
Stephanie Kirkland, Eldercare
Allison Barker, Emory
Brad Bolton, Cardinal Health NPHS
Scott Tomerlin, Walgreens
Greg Mullins, GPhA
Ben Wright, The Hudson Group
Gary Long, BotSci
Helen Sloat, Gold Dome Partners
Georgia Lehoczky, Walgreens
Tyler Riddle, ACMESA/ GAMES
Mnesha Patel, Piedmont Hospital
Phylicia Adams, Mercer COP
J. Ross Hays, Monticello Drugs
Jordan Khail, UGA College of Pharmacy
Jatoria Sanders
Jonathan Marquess, GPhA
Heather Upchurch, Emory
Bill Dahlman, Pharm Tech Forward
Chris Cline-Dahlman, Pharm Tech Forward
Olivia Kosooca, Troutman Strategies
Matt Wilson, Walgreens
Diane Sanders, Kaiser Permanente
Katie Johnston, Revelation Pharma
Christi Heys, Emory
Alycia Adams, Mercer COP
Mary Kate Snead, Guardian

Open Session

President Chang called the meeting to order at 09:02 a.m.

Approval of Minutes
President Chang advised that revisions are needed to the July 22, 2026 Open Session Minutes. The minutes will be placed on the September agenda for further review and approval.

Mr. Brinson made a motion to approve the Executive Session minutes from the July 22, 2026, meeting. Mr. Page seconded, and the Board voted in favor of the motion.

Report of Licenses Issued
Director Joiner reported that, since the last meeting, the Board has issued a total of 817 licenses, including 563 Pharmacy Technician licenses, 167 Pharmacist licenses, and 88 facility licenses.

Director Joiner advised that for FY27 the Board has issued a total of 1,254 licenses, including 886 Pharmacy Technician licenses, 246 Pharmacist licenses, and 122 facility licenses.

Mr. Brinson made a motion to ratify the list of licenses issued. Dr. Cordle seconded, and the Board voted in favor of the motion.

Petitions for Rule Waiver or Variance
Summit BHC Jacksonville, LLC dba The Pines at Willingway – Request for Variance of Rule 480-24 and Summit BHC Monroe, LLC dba Twin Lakes Recovery Center –– Request for Variance of Rule 480-24

Mr. Page presented waiver requests submitted on behalf of Summit BHC Jacksonville and Summit BHC Monroe, drug abuse treatment and education facilities, seeking authorization to maintain emergency medication kits at their facilities. The Board discussed that current rules specifically permit emergency kits in certain licensed settings, including nursing homes, hospices, and crisis stabilization units, but do not specifically provide for these types of treatment facilities.

Director Karnbach advised that the Board may wish to reevaluate the rule to determine whether additional facility types should be eligible for emergency kits. He cautioned against approving the waivers without further legal review and consultation with the state agencies responsible for licensing and overseeing the facilities. The Board also discussed the need to establish appropriate safeguards, including requirements regarding medical oversight and licensed healthcare personnel authorized to access and administer medications.

Director Joiner advised that a waiver or variance requires a showing of a unique hardship and stated that, if the issue applies broadly to similarly situated facilities, a rule amendment rather than an individual waiver would be the appropriate mechanism. Director Joiner also expressed concern regarding the applicants' characterization and alteration of previous correspondence from GDNA and advised that the requests were overly broad because they sought a waiver of the rule as a whole rather than specifically identified provisions.

Following discussion, Mr. Brinson made a motion to deny the two waiver requests and requested that a workgroup be established to review the emergency kit rule and consider possible revisions addressing additional facility types and appropriate requirements. Mr. Farmer seconded, and the Board voted in favor of the motion.

Central Admixture Pharmacy Services, Inc. (CAPS) – Request for Waiver of Rule(s) 480-10-.12(1)(e), 480-10-.12(1)(f)(1-8) and 480-10-.12(1)(h)

Mr. Page presented CAPS' requests for waivers of three provisions of Rule 480-10-.12(1). Mr. Page advised that he and Mr. Stone had reviewed the requests and recommended that the Board approve the waiver of subsection (E)(1) regarding the requirement for a Class A prescription balance or Class I or II electronic balance and weights.

Regarding subsection (F)(1)–(8), Mr. Page recommended that the Board approve the waiver only for items 1, 2, 5, and 6, and deny the waiver for items 3, 4, 7, and 8, noting that some of the listed equipment remained necessary for pharmacy operations.

Regarding subsection (H), which requires assorted sizes and types of child-resistant dispensing containers, Director Karnbach advised that federal requirements governed child-resistant packaging and recommended that the Board not waive the requirement.

Following discussion, Dr. Azzolin made a motion to approve the waiver of Rule 480-10-.12(1) subsection (E)(1); approve the waiver of Rule 480-10-.12 (1) subsection (F)(1), (2), (5), and (6) and deny Rule 480-10-.12(1) (F)(3), (4), (7), and (8); and deny the waiver of Rule 480-10.12(1) subsection (H). Dr. Cordle seconded, and the Board voted in favor of the motion.

Donalsonville Hospital – Request for Waiver of Rule(s) 480-13-.06

Mr. Page presented a rule waiver request from Donalsonville Hospital, submitted by Brian Brookins, seeking a waiver of Rule 480-13-.06, concerning drug distribution and control in hospital pharmacies. Mr. Page explained that although the request appeared to relate to

requirements for laminar flow hoods and immediate-use admixtures, the hospital requested a waiver of the entire rule rather than the specific provisions applicable to its request.

Following discussion, Dr. Azzolin made a motion to deny the waiver request because the petitioner requested a waiver of Rule 480-13-.06 in its entirety rather than identifying the specific subsection(s) applicable to the requested relief. Mr. Farmer seconded, and the Board voted in favor of the motion.

The Board also indicated that the petitioner may submit a new waiver request identifying the specific rule provisions for which a waiver is sought and may review past Board meeting minutes for guidance in identifying the applicable provisions.

Correspondence

Correspondence from Rep. Marvin Lim - Question Regarding ACIP Litigation and Georgia Vaccine Administration

Mr. Page presented correspondence from Representative Marvin Lim requesting clarification regarding the Board's August 12, 2026 guidance on vaccine administration and the effect of ongoing federal litigation concerning ACIP recommendations. Representative Lim specifically asked which ACIP recommendations Georgia pharmacists should rely upon following the March 16, 2026 federal court order; whether the applicable recommendations include the April 2026 RSV amendment for high-risk adults ages 50–59; and whether the current PREP Act declaration continues to authorize Georgia pharmacists to administer routine childhood vaccines to individuals ages 3 through 17.

Director Joiner advised that Georgia law references recommendations made by ACIP and does not specifically require the Board to follow only those recommendations currently recognized or implemented by the CDC. He advised that the Board has discretion under Georgia law to determine which ACIP recommendations it considers appropriate. Following discussion, the Board agreed to continue following the current ACIP recommendations, resulting in no change to the Board's current practice.

Regarding Representative Lim's second question, the Board agreed that its interpretation includes the ACIP recommendation concerning RSV vaccination for high-risk adults ages 50–59.

Regarding the PREP Act, Mr. Page advised that the federal authority for pharmacists to administer routine childhood vaccines that existed during the public health emergency had ended. He noted that current PREP Act authority continues for pharmacists to administer influenza and COVID-19 vaccines to individuals age three and older through December 31, 2029. The Board clarified that PREP Act authority should be considered separately from any authority available under Georgia law based upon applicable ACIP recommendations.

Director Joiner recommended that the Board consider pursuing a legislative change to create a clearer Georgia-specific framework for determining applicable vaccine recommendations rather than continuing to tie Georgia law directly to changing federal CDC and ACIP actions. He noted that such a framework could help prevent similar uncertainty when federal vaccine policies change in the future.

Georgia Drugs and Narcotics Agency – Dr. Michael Karnbach

Director Karnbach introduced Special Agent Emilie Lobeck, who covers Cobb County, Paulding County and South Fulton County.

Director Karnbach provided an update on GDNA inspection and investigation activity year-to-date. He reported that 416 inspections had been conducted, with the largest categories consisting of 215 retail pharmacy inspections and 62 researcher inspections. Other notable inspections included 42 Low THC permit inspections, 17 Remote Automated Medication System (RAMS) inspections, 11 sterile hazardous compounding inspections, and 9 non-sterile compounding inspections. Director Karnbach noted that there had been no RAMS inspections at the same time last year and attributed the increase to changes made by the Board to the RAMS permit. He advised that additional RAMS applications remain in the pipeline and that more inspections are anticipated.

Director Karnbach reported approximately 179 active and closed investigations, the majority of which involved Notifications of Loss, totaling 127. He also reported 34 complaints, with 14 involving prescription errors, which represented the largest category of complaints.

Mr. Farmer requested clarification regarding Low THC permits and whether GDNA agents wait for DEA approval before conducting an inspection. Director Karnbach explained that GDNA treats the authorization as a Low THC permit rather than a medical marijuana permit and conducts inspections based upon the Low THC permit requirements and applicable law. He acknowledged that the current statutory, regulatory, and permitting terminology has created confusion.

Director Joiner and Director Karnbach discussed the need to address the Low THC permit provisions so that the permit, rules, and applicable law are more clearly aligned. Director Karnbach stated that clarification would benefit both GDNA and the public.

Attorney General's Report – Mr. Tommy McNulty
No Report.

Executive Director's Report and Legal Services– Mr. Clint Joiner
Approved Treatment Providers
Director Joiner advised that the Georgia Board of Dentistry had discussed expanding its network of approved treatment providers and had asked staff to coordinate with other professional licensing boards, including boards regulating psychologists and other healthcare practitioners, to identify additional providers who may be interested in applying for Board approval. He noted that the current network of approved treatment providers is limited and asked whether the Pharmacy Board supported a similar effort.

The Board expressed support for expanding the network of approved treatment providers to provide licensees with greater access to treatment options. Director Joiner clarified that the intent is not to automatically recognize providers approved by other licensing boards, but rather to solicit additional qualified providers to apply for approval by the Pharmacy Board.

President Chang requested that staff provide the Board with a current list of approved treatment providers at the next meeting. Director Joiner agreed and concluded the Executive Director's Report.

Discussion Topics
Out-of-State Durable Medical Equipment (DME) Supplier Licensure
Mr. Tyler Riddle, President of MrSHomecare.com, former Chairman of the Georgia Association of Medical Equipment Suppliers (GAMES), and representative of its affiliated regional organization, addressed the Board regarding the licensure of out-of-state durable medical

equipment (DME) suppliers. Mr. Riddle expressed concern that there may be a gap between the requirements established by Georgia law and the manner in which the statutory exemption for out-of-state DME suppliers is being applied.

Mr. Riddle stated that Georgia law generally requires DME suppliers seeking Georgia licensure to maintain an office or place of business within the state, with an exception for certain Medicare-enrolled manufacturers or wholesale distributors licensed in another state. He reported that, according to 2026 facility data, Georgia currently has 608 active medical equipment supplier licenses, of which 372 are held by out-of-state providers, and questioned whether all such licensees meet the statutory requirements as manufacturers or wholesale distributors.

Mr. Riddle requested that the Board review existing out-of-state DME licenses to verify that each licensee meets the statutory exemption, require appropriate documentation of eligibility during initial application and renewal, and take appropriate action regarding any traditional out-of-state DME retailer that does not meet the statutory requirements. He emphasized that his request was intended to ensure that businesses providing the same services to Georgia patients are held to consistent regulatory standards.

Director Karnbach advised that GDNA requires out-of-state applicants relying upon the wholesale distributor provision to provide evidence of a wholesale distributor license from another state and stated that the facilities referenced by Mr. Riddle have been vetted through that process. He encouraged Mr. Riddle to submit specific facilities as complaints if he has information indicating that they do not hold the required license or may have submitted inaccurate information.

Mr. Riddle responded that his concern also involves how "wholesale distributor," "manufacturer," and "place of business in this state" are interpreted for national DME companies that may maintain Georgia locations while also applying using out-of-state addresses. Director Karnbach acknowledged that these issues may involve legal interpretation and reiterated that specific concerns regarding individual licensees should be submitted to the Board for investigation.

President Chang thanked Mr. Riddle for his comments and encouraged him to provide information regarding any specific facilities of concern.

Old Business – Follow-up

Rule 480-24-.06 – Destruction of Drugs

The Board discussed proposed amendments to Rule 480-24-.06 concerning pharmacy/ pharmacist requirements related to the destruction of drugs. Mr. Farmer advised that the proposed amendments had been reviewed with Director Karnbach and had also received input and feedback from pharmacy representatives. Based upon that review, the proposed amendments were considered ready to move forward in the rulemaking process.

Dr. Azzolin raised the question of whether the Board should delay posting the proposed amendments because of the earlier discussion concerning emergency kits. He noted that the Board had established a workgroup to review emergency-kit requirements and questioned whether it would be more efficient to complete that work and incorporate any resulting changes into Rule 480-24 at the same time, rather than proceeding with two separate amendments to the same chapter.

Director Joiner recommended that the Board proceed with the amendments that had already been

developed and were ready for consideration rather than delaying the rulemaking process while the emergency-kit workgroup completed its review. He advised that any additional amendments resulting from the emergency-kit review could be addressed separately once that work was completed.

Mr. Farmer clarified that the proposed amendments under consideration concerned pharmacy/pharmacist language regarding the destruction of drugs and were separate from another agenda item addressing drug disposal and authorized collectors.

Following discussion, Mr. Farmer made a motion to post the proposed amendments to Rule 480-24-.06 for public comment, with the understanding that additional changes could still be considered during the rulemaking/public-comment process and that amendments related to emergency kits could be addressed separately at a later time. Mr. Page seconded, and the Board voted in favor of the motion.

Loss Prevention and Reporting
The Board discussed the work completed on proposed loss prevention and reporting requirements. The workgroup explained that the initiative resulted from concerns regarding the number and, in some instances, the significant amounts of controlled substances reported through DEA Form 106 filings, as well as the limited controlled substance requirements currently contained in the Board's rules.

Mr. Page advised that the most recent version of the proposed changes, including tracked revisions, had not been placed in the August meeting materials and therefore had not been reviewed by all Board members. He agreed to make the current version available in SharePoint. The Board also discussed revisions made by the workgroup, including the deletion of a proposed provision due to concerns that some pharmacy software systems might not be capable of meeting the requirement.

President Chang emphasized that the proposed requirements could have a significant impact on pharmacies and should receive thorough review. Mr. Page agreed that increased accountability was appropriate but emphasized the importance of ensuring that the requirements were workable. Board members were asked to review the proposed language and submit questions or discussion points in advance of the next meeting. The matter will be discussed further at the September meeting.

Pending Rule Amendments/Public Hearings
President Chang noted that proposed amendments to Rule 480-15-.02 concerning pharmacy technician continuing education and prescription transfers of Schedule II controlled substances, along with the amendments to Rule 480-24-.06, were expected to move forward for posting/public hearing.

HIV Therapy/PrEP and Oral Contraceptives
The Board discussed the status of work related to HIV therapy/PrEP and oral contraceptives. Director Joiner clarified that an upcoming meeting with the Department of Public Health (DPH) related specifically to HB 1138 and oral contraceptives. Board members questioned whether additional work was currently required regarding PrEP and whether DPH had already developed relevant guidance or requirements.

Following discussion, President Chang indicated that additional information would be requested from DPH to clarify the status of the matters and determine whether further action by the

workgroup was necessary. Director Joiner recommended that the workgroup take no further action until that clarification was received.

President Chang asked whether there were any additional questions or comments. He thanked everyone for their attendance and reminded the Board that the next scheduled meeting of the Georgia State Board of Pharmacy will be held on Wednesday, September 23, 2026, at 9:00 a.m. at the Board office.

Mr. Bracewell made a motion and Mr. Farmer seconded, and the Board voted to enter into Executive Session in accordance with O.C.G.A. § 43-1-19(h) and § 43-1-2(h) to deliberate and to receive information on applications, investigative reports, and the Assistant Attorney General's report. Voting in favor of the motion were those present who included Michael Azzolin, James Bracewell, Michael Brinson, Cecil Cordle, Michael Farmer and Chuck Page.

Executive Session

Appearances: JS, CM

Cognizant's Report

Attorney General's Report – Mr. Tommy McNulty
Mr.McNulty presented the following consent orders for acceptance: BJ
Status Open Cases: AMS, VLR, RHH, TLFP, MP, ABL, EHL, SMWL, IHHR, WLA, KP, PP, ABM, LR, BJ, EPI, AA, ST, DT, SS, MLD, CI, CP, MU, TI, MAP, IK, SAI, AHMS, CP, EP, LC, CP, NGHHO, IDI, WLP
Orders: EY, CP, BRGH, DH, JR, LC
Counterproposals: AHMS, ST, AA, SP, SS

Legal Services: TAM, NHL

Applications

RJO	JCZ	FSJ	MRR	ZSD	DLATL	JB	NM	TT	JD	RN	NK	TB	AW	SG
FS	AJB	AB	NNA	TR	BNH	BB	BL	ER	OS	PN	NL	HJ		

Notices of Discipline: IRSP, AI, KTI, GCDRI, IWP, NACL, THCPL, HFPAS
Miscellaneous: RM, TO, AJ, SL, AD, VH, AMS, PW

At the close of the Executive Session, President Chang declared the meeting to be back in Open Session.

Open Session

Mr. Brinson made a motion for the Board to take the following actions:

Appearance:

Name	Request	Decision
AL	Request to Inactivate License	Approved
JS	Appearing to Discuss Application Denial	Denial overturned
CM	Appearing to Discuss Reinstatement Denial	No Show

Cognizant's Report – Mr. Michael Farmer

GDNA Case #	Licensee	Recommendation

26-2933	FP (Primary Subject – Pharmacy)/ KAG (PIC)/ SPF (Complainant)/ ABDC (Involved Party)/ BWD (Involved Party)	To the pharmacy – Referred to AG's Office
26-2968	WH (Subject Medical Director)/ JB (Complainant)/ WWL (Primary Subject)/ MS (Subject Nurse Practitioner)/ JB (Subject Owner #1)/ RB (Subject Owner #2)/ CL (Subject Owner #3)/ OII (Involved Party)/ CP (Involved Party)/ HP (Involved Party)/ TV (Involved Party)/ SLJ (Involved Party)/ KR (Involved Party)/ KJM (Involved Party)/ TB (Involved Party)	To the facility, the physician, and the nurse practitioner - Cease & Desist; Additionally - BOP office to refer the case to the Composite Medical Board and the Nursing Board
26-3128	CP (Primary Subject Pharmacy)/ LRM (PIC)/ WH (Complainant)/ FAR (Subject Floater Pharmacist)/ LNQ (Involved Party Technician)	To the PIC and the floater pharmacist Misfill Guidance #1A to the pharmacists.
26-3380	WP (Primary Subject Pharmacy)/ MBN (Complainant)/ ACXL(Subject Floater Pharmacist #2)/ SG (PIC)/ LS (Subject Floater Pharmacist #1)/ DMP (Involved Party Pharmacy Technician)/ PLT (Former PIC)/ CHAL (Involved Party)	To floater pharmacist #1 and floater pharmacist #2 - Misfill Guidance #1B to the pharmacists.
26-3521	JWR (PIC) / WG (Primary Subject Pharmacy)/ MK (Complainant)	To the PIC - Misfill Guidance #1A
26-3656	NTR (Primary Subject Pharmacy Technician) / WG (Involved Party Pharmacy)/ LH (Complainant)/ CMR (Involved Party PIC)	Revoke the technician's registration
26-3668	DDA (Subject Staff Pharmacist)/ ACCORP (Involved Party) YW (Complainant)/ NPDBUSDHHS (Complainant)/ LDC (Pharmacy)/ LDC (Involved Party Pharmacy)/ DJK (Subject Pharmacy Technician)/ LMA (Involved Party PIC)	To the staff pharmacist - Misfill Guidance #2A
26-3685	SP (Nonresident Pharmacy)/ MR (Complainant)/ IP (Subject)/ KP (Subject Unlicensed Nonresident Pharmacy)/ LP (Subject Medical Director)/ GD (Subject RN)	To the clinic, the Medical Director, and the nurse - Cease & Desist. Additionally - BOP office to refer the case to the Composite Medical Board and the Nursing Board; To the unlicensed nonresident pharmacy - Cease & Desist
26-3686	CP (Primary Subject Pharmacy)/ JMR (Subject – PIC)	To the pharmacy - Letter of Concern
26-3713	NFP (Primary Subject Pharmacy)/ ME (PIC)/ RHK (Complainant)	To the PIC - Misfill Guidance #1A
26-3714	WG (Primary Subject Pharmacy)/ SIR(PIC)/ RWO (Complainant)	To the PIC - Misfill Guidance #1A
26-4067	CP (Primary Subject Pharmacy)/ TAS (Subject PIC)	To the PIC and to the Pharmacy - Letter of Concern f
26-4076	ACI (Unlicensed Wholesale Distributor)/ ML (Involved Party)/ HIL (Primary Subject)/ GH	To the licensed wholesale distributor in Georgia – Referred to AG's Office To the unlicensed wholesale distributor – Referred to

	(Involved Party)/ RF (Involved Party)/ SP (Involved Party Designated Representative)	AG's Office to send a Cease-and-Desist order
26-4128	AKK (Subject PIC)/ CCP (Primary Subject Pharmacy)	To the pharmacy: Referred to AG's Office
26-4313	DG (Primary Subject Pharmacy Intern)/ PP (Subject Pharmacy #1)/ TT (Involved Party Staff Pharmacist #1)/ MH (Involved Party Staff Pharmacist #2)/ AKJ (Complainant District Manager)/ PSM (Involved Party Pharmacy #2)/ NKU (Involved Party PIC)	To the pharmacy intern: referred to AG's Office
26-3304	PMC (Primary Subject)/ VC (Complainant)/ PP (Subject Unlicensed Wholesale Distributor)	Close and the BOP office to refer the case to the Composite Medical Board.
26-3682	AC (Primary Subject Physician)/ RK (Complainant)/ KD (Involved Party Pharmacy)/ KD (Involved Party Pharmacy)/ KD (Involved Party Pharmacy)/ KD (Involved Party Pharmacy)/ KD (Involved Party Pharmacy)	Close and the BOP office to refer the case to the Composite Medical Board.
26-2279	WG (Pharmacy)/ OF (PIC)/ HS (Complainant)/ KS (Involved Party Pharmacist)/ NR (Involved Party Pharmacist)/ MS (Involved Party Pharmacist)/ MJ (Tech)/ VG (Tech)	Close
26-3161	CP (Primary Subject Pharmacy)/ VW (PIC)/ CF (Complainant)	Close
26-3166	KD (Subject)/ RK (PIC)/ ES (Complainant)/ JFS (Involved Party Pharmacist)/ KE (Involved Party Pharmacist)/ KTCF (Involved Party)/ BP (Involved Party)	Close
26-3307	GI (Primary Subject Pharmacy)/ CB (Complainant)	Close
26-3309	WG (Primary Subject/ MP (Involved Party PIC)/ DP (Complainant)/ SM (Involved Party Staff Pharmacist)	Close
26-3376	TND (Involved Party PIC)	Close
26-3428	SN (Involved Party Pharmacist)/ TC (Complainant)/ CB (Involved Party Pharmacist)/ WHS (Primary Subject)/ JE (Involved Party Pharmacist)/ AD (PIC)	Close
26-3482	WRFP (Primary Subject Pharmacy)/ TM (Involved Party PIC)/ JJ (Complainant)	Close
26-3540	WSPN (Primary Subject Pharmacy)/ KLT (Involved Party PIC)/ MP (Complainant) / AI (Involved Party Staff Pharmacist) / SDLC (Involved Party Pharmacy Tech)/ SG (Involved	Close

	Party Pharmacy Tech)	
26-3689	WP (Primary Subject)/ CO (Involved Party PIC)/ LKA (Complainant)	Close
26-3711	PP (Primary Subject)/ NG (Involved Party PIC)/ GT (Complainant)/ LL (Involved Party Pharmacy Tech)/ SW (Involved Party Pharmacy Tech)/ KT (Subject Staff Pharmacist)/ PSMI (Subject Pharmacy #2)/ KAW (Involved Party Pharmacist)/ CC (Involved Party Pharmacy Tech)	Close
26-3777	NCMWDC (Primary Subject)/ Anonymous (Complainant)/ KZ (Involved Party)	Close
26-3794	MM (Involved Party Pharmacist)/ CP (Primary Subject)/ AT (Complainant)/ MA (Subject PIC)/ MFMH (Subject Floater Pharmacist) / ZJ (Involved Party Tech)/ RP (Involved Party Tech)	Close

Legal Services

Licensee	Violation	Decision
TAM	Facility changed locations 11/18/19 & did not notify the Board; New Application submitted 07/06/2026	Public Consent Order with Fine
NHL	Facility changed ownership on 12/31/22 & never notified the Board.	Public Consent Order with Fine

Applications

Name	Type of License	Decision
RJO	Pharmacy Technician	Approved
JCZ	Pharmacy Technician	Approved
FSJ	Pharmacy Technician	Approved
MR	Pharmacy Technician	Approved
ZSD	Pharmacy Technician	Approved
DL	Pharmacy Technician	Approved
JB	Pharmacy Technician	Approved
NM	Pharmacy Technician	Approved
TT	Pharmacy Technician	Approved
JD	Pharmacy Technician	Approved
RN	Pharmacy Technician	Approved
NK	Pharmacy Technician	Approved
TB	Pharmacy Technician	Approved
AW	Pharmacy Technician	Approved
SG	Pharmacy Technician	Approved
FS	Pharmacy Technician	Approved with conditions
AJB	Pharmacy Technician	Denied
AB	Pharmacy Technician	Approved

NA	Pharmacy Technician	Approved
TR	Pharmacy Technician	Approved
BH	Pharmacy Technician	Approved with conditions
BB	Pharmacist	Approved
BL	Pharmacist	Approved
ER	Pharmacist	Approved
OC	Certification of DTM	Approved
PN	Certification of DTM	Approved
NL	Certification of DTM	Approved
HJ	Nuclear Pharmacist	Approved

Notices of Discipline: The Board reviewed the notices and agreed that these notices are to be taken as information only and that no further action is necessary at this time.

Miscellaneous:

Licensee	Issue	Decision
RM	Request to Terminate Probation	Approved
TO	Response to Letter of Concern	Approved
AJ	Request for Refund	Denied
SL	Selfe Report Arrest	Take as Information
AD	Response to Letter of Concern	Take as Information
VH	Request to Extend Intern License	Approved
AMS	Request to Terminate Probation	Approved
NPW/ EWP	Request for an Extension to keep both licenses active until the approval has been received from the DEA	Approved

Mr. Brinson seconded, and the Board voted unanimously in favor of the motion. There being no further business to discuss, the meeting was adjourned at 1:22 p.m.

The next scheduled meeting of the Georgia Board of Pharmacy will be held on Wednesday, September 23, 2026 at 9:00 a.m. at the Georgia State Board of Pharmacy, 2 Martin Luther King, Jr. Drive SW, East Tower, 11th Floor, Atlanta, GA 30334.

Minutes recorded by Angela Johnson, Board Administrative Secretary
Edited by J. Clinton Joiner, II, Executive Director

The views, thoughts, and opinions expressed by individual members of the board are solely those of the individual and do not necessarily reflect the official policy or position of the Georgia State Board of Pharmacy, or any other individual member of the board.